TriSalus Life Sciences, Inc.

MedTech Acquisition Corp (Nasdaq: MTAC) is a special purpose acquisition company that priced its initial public offering in 2021 with a stated focus on the medical technology and healthcare sector. The SPAC entered into a definitive business combination agreement with TriSalus Life Sciences, Inc., an oncology-focused medtech company developing pressure-enabled drug delivery systems designed to improve treatment of liver and pancreatic cancers. The quarterly report filed with the SEC on November 10, 2022 reflects MTAC's status as a pre-combination vehicle, with the proposed merger pending at that time. For comprehensive SPAC filing data, deal timelines, and sponsor analytics on MTAC and the broader SPAC market, sign up for full access at SpacDesk.